|Last Price$8.68||Day Change (%)1.05%|
|Open Price$8.67||Day Change ($)0.09|
|Day Range8.62–8.74||52-Week Range3.55–8.74|
As of Fri 7/22/2016 5:00:00 PM | USD
Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
Lack of competitive advantages may mean these companies aren't the bargains they seem to be.
We see opportunity as fleeing investors trigger an irrational sell-off.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
The five biotech ETFs have very different portfolios with markedly different performance.